Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
Mirvetuximab soravtansine
No preference
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05445778IIIHigh grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after second line platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance)Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRα-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus BevacizumabLA, NV, NY, NCView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Mirvetuximab soravtansineAnti-FOLR1-mab Maytansinoid Conjugate, IMGN853, M9346A-sulfo-SPDB-DM4ADC: anti-FOLR1 + microtubule destabilizer (DM4)Approved in Ovarian Cancer
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer

If you have any questions or would like help with your search, please call us at: 858-657-0282 or email us at